Bernstein Maintains Outperform on Vertex Pharmaceuticals, Lowers Price Target to $572

Benzinga Newsdesk www.benzinga.com Negative 94.3%

Neg 94.3% Neu 0% Pos 0%

Bernstein analyst William Pickering maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and lowers the price target from $577 to $572.